Table 1.

Patient’s characteristics.

	N = 32 (%)
Gender, no (%)
Female	2 (6.2%)
Male	30 (93.8%)
PID subtype, no (%):
CID	17 (53.1%)
PIRD	6 (18.8%)
CGD	9 (28.1%)
Age (years) of first symptoms (median, range)	1.70 [0.06;34.3]
Age (years) at clinical diagnosis (median, range)	3.81 [0.27;34.8]
Time between first symptoms and diagnosis (median, range)	0.41 [0.00;14.2]
Age at transplant (median, range)	26.9 [17.2;41.4]
Delay between diagnosis and allo-HSCT (median, range)	19.4 [2.03;38.3]
Active infection at time of allo-HSCT	16 (50.0%)
History of AI	20 (62.5%)
Active AI at time of allo-HSCT, no (%)	13/20 (65.0%)
History of lymphoma, no (%)	9 (28.1%)
Preallo-HSCT chemotherapy, no (%)	9 (28.1%)
IgRT prior to allo-HSCT, no (%)	9 (59.4%)
Splenectomy, no (%)	7 (21.9%)
Age at splenectomy (median, range)	8.00 [3.00;36.0]
HTC-CI score, no (%)
High (>2)	16 (50%)
Intermediate (1–2)	13 (40.6%)
Low (0)	3 (9.38%)
Main organ contributing to HCT-CI score (%)
Pulmonary	16 (50%)
Hepatitis	4 (12.5%)
Active IBD	4 (12.5%)

AI autoimmunity/autoinflammation (AI), HCT-CI hematopoietic cell transplantation-comorbidity index.